CompletedPhase 3NCT05072080
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Studying Chikungunya
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Principal Investigator
- Patrick Ajiboye, MDBavarian Nordic
- Intervention
- CHIKV VLP/adjuvant(biological)
- Enrollment
- 3258 enrolled
- Eligibility
- 12-64 years · All sexes
- Timeline
- 2021 – 2023
Study locations (30)
- Optimal Research, LLC, Huntsville, Alabama, United States
- Alliance for Multispecialty Research - Mobile, Mobile, Alabama, United States
- Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States
- Velocity Clinical Research, Banning, Banning, California, United States
- Optimal Research, LLC, San Diego, California, United States
- Lynn Institute of the Rockies, Colorado Springs, Colorado, United States
- Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
- Accel Research Sites-DeLand Clinical Research Unit, Lake Mary, Florida, United States
- Optimal Research, LLC, Melbourne, Florida, United States
- Suncoast Research Associates, LLC, Miami, Florida, United States
- Synexus Clinical Research US, Inc., Pinellas Park, Florida, United States
- Palm Beach Research Center, West Palm Beach, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Velocity Clinical Research, Boise, Meridian, Idaho, United States
- Synexus Clinical Research US, Inc., Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Emergent BioSolutions
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05072080 on ClinicalTrials.govOther trials for Chikungunya
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07555392A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Bharat Biotech International Limited
- ENROLLING BY INVITATIONNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ACTIVE NOT RECRUITINGNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07520279Xpert® Tropical Fever Test on GeneXpert® Edge X SystemCepheid
- ACTIVE NOT RECRUITINGNCT06651372The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return TravelersUniversity Hospital, Strasbourg, France
- RECRUITINGNCT07120724Real-World Study on Chinese Medicine for Treating Chikungunya FeverGuangzhou University of Traditional Chinese Medicine
- RECRUITINGPHASE3NCT07003984A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Bavarian Nordic